Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189351 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL3519708 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL30768150 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL21736594 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL21736595 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| Cyclo(Prolylglycyl) SCHEMBL3016264 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| Cyclo(Prolylglycyl) SCHEMBL4247464 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| Cyclo(Prolylglycyl) SCHEMBL4243772 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL19605682 | 0.93 | KDM4E (0.39) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL19605610 | 0.93 | KDM4E (0.39) | ALDH1A1KDM4EMAPTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772227-B2 | Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid CB1 receptor agonists | N.V. ORGANON (NL) | 2010-08-10 | — | — | US | disclosed |
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | AKZO NOBEL N.V. (NL) | 2007-04-19 | — | — | US | disclosed |
| EP-1696930-B1 | TRICYCLIC 1-((3-INDOL-3-YL)CARBONYL)PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS | ORGANON NV (NL) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | OPRD1, OPRK1, OPRM1 | ALDH1A1 2439/4885KDM4E 2539/4885MAPT 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.